The global pharmaceutical landscape is rapidly evolving, with innovation cycles becoming shorter and the demand for high-quality, large-scale manufacturing rising significantly. This shift has placed CDMO partnerships at the centre of modern drug development. As India emerges as a global powerhouse for CDMO pharma services, companies worldwide are evaluating partners through a new lens—one defined by measurable, quantifiable excellence.
Today, the “Best CDMO in India” is no longer determined only by capacity or cost. Instead, global clients assess a CDMO’s value using robust performance metrics that reflect technological maturity, quality standards, operational efficiency, sustainability, and workforce strength.
One of the first metrics is manufacturing volume and infrastructure scale. Large-scale production allows CDMOs to support multiple global markets, reduce cost per unit, and ensure supply continuity. Companies with multiple GMP-compliant plants, diverse dosage capabilities, and strong R&D support score highest in partner evaluations.
Another rising metric is regulatory strength. CDMOs today must demonstrate compliance with WHO-GMP, USFDA, EMA, MHRA, TGA, and other global regulatory frameworks. A strong history of audits, zero-critical observations, and transparent quality systems significantly boosts a CDMO’s credibility.
A modern CDMO is also evaluated for its digitalisation and automation capabilities. Manufacturing excellence now requires automated material handling, QMS, data integrity systems, and AI-led quality tools. These not only improve accuracy but also reduce human error, cycle times, and deviations.
Sustainability is another essential benchmark. Zero-harm operations, CO₂ reduction, water conservation, and waste management represent global expectations. Clients increasingly prefer partners with measurable environmental impact reduction.
This is where Akums emerges among the top examples. As one of the largest CDMOs in India, Akums demonstrates excellence across every modern metric. With a robust multi-plant ecosystem, Akums handles massive manufacturing volumes across oral solids, liquids, injectables, derma, nutraceuticals, herbal formulations, and specialty dosage forms. Its plants are backed by advanced technologies, digital systems, and strong compliance cultures.
Akums’ workforce strength is another differentiator. Employing 16,000+ professionals, including a growing percentage of skilled women employees, Akums ensures an inclusive and future-ready manufacturing environment. Its focus on a zero-harm safety record, CO₂ reduction initiatives, and systemic water reduction programs further elevate it as a sustainability-driven CDMO.
In addition, Akums exports to numerous global markets, serving leading pharmaceutical companies with both branded and generic formulations. This broad market presence highlights its capability to meet international quality expectations consistently.
As India climbs to the forefront of global CDMO pharmaceutical leadership, these measurable performance benchmarks are redefining what excellence means. Companies that combine strong infrastructure, regulatory compliance, sustainability, digital maturity, and workforce excellence will continue to stand out as preferred global partners.
For organizations seeking the Best CDMO in India, understanding these metrics—and evaluating partners against them—will be crucial to building successful, long-term collaborations.
